Plain-English translation of NCT06880198 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing a nutritional product called Impact® to see if it can help reduce the side effects that patients experience when receiving immunotherapy for advanced melanoma. The medication being tested is given for about 5 weeks in a specific schedule, starting one week before your standard anti-PD1 immunotherapy begins. Researchers will compare how patients who receive Impact® fare compared to similar patients from past studies who did not receive this nutritional support.
Immunotherapy is a powerful treatment for advanced melanoma, but it can cause significant side effects related to the immune system. This study is exploring whether this nutritional support product might help reduce these immune-related side effects, making treatment safer and more tolerable for patients.
You likely qualify if…
You likely don't qualify if…
You would receive Impact® as oral bricks (a specific food format) starting one week before your scheduled immunotherapy begins—taking two bricks per day for 21 days, then one brick per day for 14 days. After that initial phase, you would continue receiving this nutritional support alongside your standard immunotherapy, which your oncologist will manage as usual. The study team will monitor you for side effects and compare your experience to similar patients from previous studies.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
Italy